Immunotherapy for the Treatment of Advanced Nasopharyngeal Carcinoma: a Promising New Era

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2022 Jul 25

PMID 35876949

Authors

Shaoli Wang

Siying Chen

Qionglei Zhong

Yan Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: Nasopharyngeal carcinoma (NPC) is ranked the top otorhinolaryngology malignant tumors in the world. However, the general prognosis of recurrent and metastatic (R/M) nasopharyngeal carcinomas (NPCs) remains poor, and current surgery and chemoradiotherapy do not generate satisfactory outcomes.

Methods: As a new therapeutic choice, immunotherapy, especially with regard to the development of checkpoint inhibitors including PD-1 and CTLA-4 inhibitors have made considerable progress in recent years. As Epstein-Barr virus (EBV) infection is associated with increased risk of NPC, EBV-related immunotherapy may lead to a breakthrough in advanced NPCs.

Results: In this review, we summarized the clinical characters of NPC, and several past and ongoing clinical trials of checkpoint inhibitors and EBV-CTLs (CTLs: cytotoxic T lymphocytes) in R/M NPC immunotherapy.

Conclusion: We conclude that although the evaluated effects of new immunotherapy drugs have brought us hope on NPC treatment, further phase II-III trials with larger samples are still required to improve the proportion and scheme of drug collocation for better clinical outcomes and less drug-related safety.

Citing Articles

The IL-10/STAT3 Axis Nasopharyngeal Carcinoma Cancer stem cell and radio resistance.

Wang L, Zhao Y, Wang Y, Xing L, Duan Y, Zang H Sci Rep. 2024; 14(1):31943.

PMID: 39738457 PMC: 11685382. DOI: 10.1038/s41598-024-83423-2.

Role of N6-methyladenosine methylation in nasopharyngeal carcinoma: current insights and future prospective.

Zhao Y, Li J, Dian M, Bie Y, Peng Z, Zhou Y Cell Death Discov. 2024; 10(1):490.

PMID: 39695216 PMC: 11655975. DOI: 10.1038/s41420-024-02266-y.

PD-1 inhibitors combined with chemotherapy versus chemotherapy alone: efficacy and prognostic analysis in recurrent metastatic nasopharyngeal carcinoma.

Liu Y, Wang Z, Wu B, Zhu Y, Liang X Am J Transl Res. 2024; 16(6):2622-2632.

PMID: 39006268 PMC: 11236648. DOI: 10.62347/PAAP2909.

Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.

Lian D, Gan Y, Xiao D, Xuan D, Chen Y, Yang Y Cancer Med. 2024; 13(10):e7243.

PMID: 38752448 PMC: 11097128. DOI: 10.1002/cam4.7243.

Enhancing Nasopharyngeal Carcinoma Survival Prediction: Integrating Pre- and Post-Treatment MRI Radiomics with Clinical Data.

Dang L, Hung S, Le N, Chuang W, Wu J, Huang T J Imaging Inform Med. 2024; 37(5):2474-2489.

PMID: 38689151 PMC: 11522233. DOI: 10.1007/s10278-024-01109-7.

References

Benasso M . Induction chemotherapy for squamous cell head and neck cancer: a neverending story?. Oral Oncol. 2013; 49(8):747-52. DOI: 10.1016/j.oraloncology.2013.04.007. View

Bommareddy P, Shettigar M, Kaufman H . Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018; 18(8):498-513. DOI: 10.1038/s41577-018-0014-6. View

Chan J, Wei W . Three-dimensional endoscopy for endoscopic salvage nasopharyngectomy: Preliminary report of experience. Laryngoscope. 2017; 128(6):1386-1391. DOI: 10.1002/lary.26993. View

Chen B, Chapuy B, Ouyang J, Sun H, Roemer M, Xu M . PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013; 19(13):3462-73. PMC: 4102335. DOI: 10.1158/1078-0432.CCR-13-0855. View

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

Chen F, Lin L, Liang J, Tan S, Ong E, Luo Y . Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. Ther Adv Med Oncol. 2021; 13:17588359211052417. PMC: 8554575. DOI: 10.1177/17588359211052417. View

Chia W, Teo M, Wang W, Lee B, Ang S, Tai W . Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 2013; 22(1):132-9. PMC: 3978790. DOI: 10.1038/mt.2013.242. View

Chow J, Ngan R, Cheung K, Cho W . Immunotherapeutic approaches in nasopharyngeal carcinoma. Expert Opin Biol Ther. 2019; 19(11):1165-1172. DOI: 10.1080/14712598.2019.1650910. View

Dovedi S, Cheadle E, Popple A, Poon E, Morrow M, Stewart R . Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clin Cancer Res. 2017; 23(18):5514-5526. DOI: 10.1158/1078-0432.CCR-16-1673. View

10.

Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T . EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget. 2014; 5(23):12189-202. PMC: 4322961. DOI: 10.18632/oncotarget.2608. View

11.

Fang W, Yang Y, Ma Y, Hong S, Lin L, He X . Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018; 19(10):1338-1350. DOI: 10.1016/S1470-2045(18)30495-9. View

12.

Galluzzi L, Vacchelli E, Bravo-San Pedro J, Buque A, Senovilla L, Baracco E . Classification of current anticancer immunotherapies. Oncotarget. 2014; 5(24):12472-508. PMC: 4350348. DOI: 10.18632/oncotarget.2998. View

13.

Hsu C, Lee S, Ejadi S, Even C, Cohen R, Le Tourneau C . Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol. 2017; 35(36):4050-4056. DOI: 10.1200/JCO.2017.73.3675. View

14.

Jiang F, Yu W, Zeng F, Cheng G, Xu J, Yang S . PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma. BMC Cancer. 2019; 19(1):503. PMC: 6537411. DOI: 10.1186/s12885-019-5689-y. View

15.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View

16.

Larkin J, Hodi F, Wolchok J . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(13):1270-1. DOI: 10.1056/NEJMc1509660. View

17.

Lee H, Okuda K, Gonzalez F, Patel V . Current Perspectives on Nasopharyngeal Carcinoma. Adv Exp Med Biol. 2019; 1164:11-34. DOI: 10.1007/978-3-030-22254-3_2. View

18.

Ma B, Lim W, Goh B, Hui E, Lo K, Pettinger A . Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018; 36(14):1412-1418. PMC: 5941615. DOI: 10.1200/JCO.2017.77.0388. View

19.

Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson J . Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. Front Oncol. 2019; 9:122. PMC: 6414812. DOI: 10.3389/fonc.2019.00122. View

20.

Ostrand-Rosenberg S, Horn L, Ciavattone N . Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy. Front Oncol. 2019; 9:215. PMC: 6454107. DOI: 10.3389/fonc.2019.00215. View